Harnessing diversity to study Alzheimer's disease: A new iPSC resource from the NIH CARD and ADNI.
Journal
Neuron
ISSN: 1097-4199
Titre abrégé: Neuron
Pays: United States
ID NLM: 8809320
Informations de publication
Date de publication:
16 Feb 2024
16 Feb 2024
Historique:
received:
22
01
2024
revised:
26
01
2024
accepted:
26
01
2024
medline:
23
2
2024
pubmed:
23
2
2024
entrez:
22
2
2024
Statut:
aheadofprint
Résumé
The iDA Project (iPSCs to Study Diversity in Alzheimer's and Alzheimer's Disease-related Dementias) is generating 200 induced pluripotent stem cell lines from Alzheimer's Disease Neuroimaging Initiative participants. These lines are sex balanced, include common APOE genotypes, span disease stages, and are ancestrally diverse. Cell lines and characterization data will be shared openly.
Identifiants
pubmed: 38387456
pii: S0896-6273(24)00052-7
doi: 10.1016/j.neuron.2024.01.026
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Published by Elsevier Inc.
Déclaration de conflit d'intérêts
Declaration of interests A.J.S. has received support from Avid Radiopharmaceuticals, a subsidiary of Eli Lilly (in-kind contribution of PET tracer precursor), and has participated in scientific advisory boards (Bayer Oncology, Eisai, Novo Nordisk, and Siemens Medical Solutions USA, Inc) and an observational study monitoring board (MESA, NIH NHLBI). He also serves as editor-in-chief for Brain Imaging and Behavior, a Springer-Nature journal, and serves on four other NIA external advisory committees. M.A.N. currently serves on the scientific advisory board for Character Bio Inc. and is a scientific founder at Neuron23 Inc.